Trinity Legacy Partners LLC Boosts Position in Pfizer Inc. (NYSE:PFE)

Trinity Legacy Partners LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 3.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 107,348 shares of the biopharmaceutical company’s stock after buying an additional 3,838 shares during the quarter. Pfizer accounts for about 2.2% of Trinity Legacy Partners LLC’s portfolio, making the stock its 15th largest holding. Trinity Legacy Partners LLC’s holdings in Pfizer were worth $5,501,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of PFE. Karp Capital Management Corp purchased a new position in Pfizer during the 3rd quarter worth approximately $27,000. Worth Asset Management LLC purchased a new position in shares of Pfizer during the 1st quarter valued at approximately $29,000. Delos Wealth Advisors LLC increased its holdings in shares of Pfizer by 100.0% during the 3rd quarter. Delos Wealth Advisors LLC now owns 800 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 400 shares in the last quarter. Legend Financial Advisors Inc. purchased a new position in shares of Pfizer during the 3rd quarter valued at approximately $42,000. Finally, Align Wealth Management LLC purchased a new position in shares of Pfizer during the 4th quarter valued at approximately $45,000. 67.62% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.7 %

Shares of PFE stock opened at $40.10 on Friday. The company’s 50-day moving average price is $43.26 and its 200-day moving average price is $46.03. The company has a current ratio of 1.22, a quick ratio of 1.00 and a debt-to-equity ratio of 0.34. The stock has a market cap of $225.33 billion, a price-to-earnings ratio of 7.32, a PEG ratio of 1.33 and a beta of 0.64. Pfizer Inc. has a twelve month low of $39.23 and a twelve month high of $56.32.

Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.11. The firm had revenue of $24.30 billion for the quarter, compared to analysts’ expectations of $24.40 billion. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The company’s revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS. As a group, equities analysts predict that Pfizer Inc. will post 3.33 earnings per share for the current year.

Wall Street Analyst Weigh In

PFE has been the subject of several recent research reports. Wells Fargo & Company cut their target price on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating for the company in a report on Friday. Credit Suisse Group dropped their price target on shares of Pfizer from $54.00 to $50.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 1st. Barclays dropped their price target on shares of Pfizer from $49.00 to $44.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 1st. UBS Group set a $45.00 price target on shares of Pfizer in a research note on Tuesday. Finally, Jefferies Financial Group started coverage on shares of Pfizer in a research note on Monday, March 6th. They issued a “hold” rating and a $43.00 price target on the stock. Nine research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average price target of $50.38.

About Pfizer

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.